This ruling has no material impact on Teva's stock. The underlying EpiPen antitrust MDL continues, but today's order is a routine discovery dispute over a non-party law firm's search terms and redactions. Monitor for substantive rulings on class certification, summary judgment, or trial, which would carry real financial exposure.
TEVA drugs
TEVA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+20- T+0 · Aug 26 $37.92entry
- T+1 · 3mo ago −0.79%α −1.45% · $37.62
- T+5 · 3mo ago −1.13%α −1.01% · $37.49
- T+20 · 8w ago +6.07%α +5.67% · $40.22
- T+57 · todayOpen
- T+60 · in 2d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
A federal magistrate judge in Kansas granted in part and denied in part a motion to compel non-party law firm Goodwin Procter to re-run document searches in the long-running EpiPen antitrust MDL against Teva. The court denied plaintiffs' request for additional search terms as untimely and insufficiently justified, but ordered Goodwin to submit two redacted email strings for in camera review. This is a routine discovery dispute with no material financial exposure or business impact on Teva, the ruling does not address liability, damages, or any substantive claim in the underlying antitrust case.
Court Ruling Details
Key Facts
- Ruling is a discovery dispute over non-party law firm Goodwin Procter's document production in the EpiPen antitrust MDL (Case 2:22-cv-02501-DDC-TJJ).
- Court denied plaintiffs' request to compel Goodwin to run additional search terms, finding the motion untimely and the burden outweighed the likely benefit.
- Court granted in part plaintiffs' request regarding two redacted email strings, ordering Goodwin to submit unredacted versions for in camera review.
- No damages, injunction, or liability finding was made against Teva, the ruling concerns only procedural discovery obligations of a non-party law firm.
- The underlying case is a multi-district antitrust litigation regarding EpiPen pricing, but this specific ruling has no financial exposure for Teva.
Financial Impact
No financial impact, this is a procedural discovery ruling with no damages, penalties, or business restrictions imposed on Teva.
Risk Factors
- The underlying EpiPen antitrust MDL could eventually result in material damages or injunctive relief against Teva, but today's ruling does not change that risk profile.
- If the in camera review of the two email strings reveals discoverable material, it could lead to further discovery disputes, but the scope is narrow.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 court opinion.
| Document | Accession Number |
|---|---|
| COURT-RULING Data (Synthetic) | court-9d441e92f6-TEVA |
Track record
61 reports on TEVA
6 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +33.06% at T+60 after the Jul 20, 2026 report. 15 of 17 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $43.16 Now $42.57 −1.37% settles Feb 12
- Nov 12, 20264d ago 3 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $44.50 Now $42.57 −4.34% settles Feb 11
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $43.65 Now $42.57 −2.47% settles Feb 10
- Nov 10, 20266d ago 144 Neutral 3/10 Entry $43.24 Now $42.57 −1.55% settles Feb 9
- Nov 10, 20266d ago SC 13G/A Neutral 3/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $42.40 Now $42.57 +0.40% settles Feb 8
- Nov 6, 202610d ago Insider Cluster Neutral 3/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $42.97 Now $42.57 −0.93% settles Feb 5
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $42.61 Now $42.57 −0.09% settles Feb 4
US Market Status
Subscribe to SecBot
Get Real-Time Court Ruling Intelligence
Market-moving court rulings analyzed within minutes. Patent verdicts, antitrust decisions, class certifications, and more, parsed and scored by AI.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers